Novartis suspends 24,000-patient elinogrel trial in chronic CHD
This article was originally published in Scrip
Executive Summary
Novartis has "suspended indefinitely" a planned 24,000-patient Phase III study in chronic coronary heart disease (CHD) of elinogrel, the antiplatelet candidate that it licensed for up to $575 million through a deal with Portola Pharmaceuticals in 2009.